Neuphoria Therapeutics Inc. (NEUP) stock
NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
$2.48−0.07 (-2.75%)
Close on Nov 16, 2026Market cap $74.56KP/E –Yield –
Neuphoria Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2026 it was $1.17M, down 92.5% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $1.17M | -92.5% |
| FY2025 | Jun 30, 2025 | $15.65M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $15.00M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $662.72K | – |
See a number that looks wrong?